Bank of America Securities: Lowering SAMSONITE (01910) target price to HK$20, reaffirming "buy" rating.
The company believes that the fall in oil prices can slightly relieve the pressure on household budgets, and with demand gradually recovering, group sales will resume positive growth in the second half of 2026.
Bank of America Securities released a research report stating that SAMSONITE (01910) is continuously affected by inflation pressure, impacting consumer sentiment in its main markets. In the second quarter, excluding the impact of exchange rates, sales, adjusted EBITDA, and net profit after tax will decrease by 1%, 20%, and 25% respectively compared to the previous year. The target price has been lowered from HK$22 to HK$20, with a reiterated "buy" rating.
The bank has adjusted the company's adjusted net profit forecast for 2026-2027 to $250 million and $280 million, respectively, reflecting lower sales and profit margin expectations. However, they believe that the company's brand holds a leading position in its product categories and that its valuation is attractive. They also believe that falling oil prices could slightly ease household budget pressures, and as demand gradually recovers, the group's sales will resume positive growth in the second half of 2026.
Related Articles

JENSCARE-B(09877): The first group of subjects implanted with the LuX-ValvePlus transcatheter tricuspid valve replacement system have completed the key pivotal trial approved by the FDA.

SSY GROUP (02005): Procured drug production registration certificate for Fenobet Acid Choline Sustained-Release Capsules (135mg).
.png)
UNITED LAB (03933) received a milestone payment of $13.5 million from Novonordisk for the exclusive licensing agreement for UBT251.
JENSCARE-B(09877): The first group of subjects implanted with the LuX-ValvePlus transcatheter tricuspid valve replacement system have completed the key pivotal trial approved by the FDA.

SSY GROUP (02005): Procured drug production registration certificate for Fenobet Acid Choline Sustained-Release Capsules (135mg).

UNITED LAB (03933) received a milestone payment of $13.5 million from Novonordisk for the exclusive licensing agreement for UBT251.
.png)
RECOMMEND





